Scrip's Rough Guide To IL-2: Mother Of All Cytokines
Executive Summary
Nektar Therapeutics, Alkermes and Roche are among the companies with new solutions for more safely targeting an old cytokine well validated in cancer immunotherapy. Top execs explain how and why.
You may also be interested in...
Alkermes Thinks Nemvaleukin Could Succeed Where Other IL-2 Candidates Have Failed
On the heels of clinical failures for Nektar’s pegylated IL-2 candidate bempeg, Alkermes’ CEO argued its high-dose IL-2 for cancer is well differentiated during earnings call. Schizophrenia drug Lybalvi posted solid first full-quarter revenue, prescription numbers.
Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames
Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames
Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders
Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.